小细胞肺癌诊疗新进展

New Advances in the Treatment for Small Cell Lung Cancer

小细胞肺癌(small cell lung cancer, SCLC)是一种恶性程度高、病情进展快、预后差、易复发的难治性癌症。在过去的30余年中,SCLC以化疗和放疗为主的传统治疗策略并未出现明显变化,临床需求的有效治疗方式迫在眉睫。精准医学的快速发展揭示了SCLC的分子生物学特征,故其诊疗进入一个新的时代指日可待。目前已有研究显示抗新生血管生成药物、免疫治疗等一定程度上提高了SCLC治疗的疗效,并且有涌现出更多的关于SCLC诊疗方式的研究,从而开辟了SCLC治疗的新领域,给患者带来更多生存获益。针对SCLC分子病理的靶向治疗、抗新生血管生成药物、免疫治疗方面新的研究崭露头角,本文对SCLC新的诊疗方式进行综述,以示读者,为其临床治疗提供新的指导。

Small cell lung cancer(SCLC)is a refractory cancer with high degree of malignancy,rapid disease progression,poor prognosis and easy recurrence.In the past 30 years,the traditional treatment of SCLC,mainly chemotherapy and radiotherapy,has not changed significantly,and the effective treatment method for clinical needs is extremely urgent.The rapid development of precision medicine has revealed the molecular biological characteristics of SCLC,so its diagnosis and treatment will into a new era.At present,some studies have shown that anti-angiogenic drugs,immunotherapy and so on have improved the efficacy of SCLC treatment to some extent,and there are more studies on the diagnosis and treatment of SCLC,so a new field of SCLC treatment are coming and bringing more survival benefits to patients.New studies on targeted therapy,anti-angiogenesis drugs and immunotherapy of molecular pathology of SCLC are emerging.This paper reviews the new diagnosis and treatment methods of SCLC to provide new guidance for its clinical treatment.